<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Prev Med</journal-id><journal-id journal-id-type="iso-abbrev">Am J Prev Med</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>American journal of preventive medicine</journal-title></journal-title-group><issn pub-type="ppub">0749-3797</issn><issn pub-type="epub">1873-2607</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10074824</article-id><article-id pub-id-type="pmcid-ver">PMC10074824.1</article-id><article-id pub-id-type="pmcaid">10074824</article-id><article-id pub-id-type="pmcaiid">10074824</article-id><article-id pub-id-type="manuscript-id">NIHMS1884413</article-id><article-id pub-id-type="pmid">36257884</article-id><article-id pub-id-type="doi">10.1016/j.amepre.2022.08.016</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1884413</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1884413</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>ECONOMIC IMPACT OF UNIVERSAL HCV TESTING FOR MIDDLE AGED ADULTS WHO INJECT DRUGS</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="X">Xinyi</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Diaby</surname><given-names initials="V">Vakaramoko</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vouri</surname><given-names initials="SM">Scott Martin</given-names></name><degrees>PharmD, Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lo-Ciganic</surname><given-names initials="W">Weihsuan</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parker</surname><given-names initials="R">Robert</given-names></name><degrees>Ph.D.</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wei</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="SH">Shao-Hsuan</given-names></name><degrees>B.S.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wilson</surname><given-names initials="DL">Debbie L.</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Henry</surname><given-names initials="L">Linda</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="H">Haesuk</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pharmaceutical Outcomes &amp; Policy, University of Florida College of Pharmacy, Gainesville, Florida</aff><aff id="A2"><label>2</label>Center for Drug Evaluation and Safety (CoDES), University of Florida, Gainesville, Florida</aff><aff id="A3"><label>3</label>Department of Biostatistics, University of Florida College of Public Health &amp; Health Professions College of Medicine, Gainesville, Florida</aff><author-notes><corresp id="CR1">Corresponding Author: Haesuk Park, Ph.D., Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, 1225 Center Drive HPNP Building Room 3325, Gainesville, Florida 32610; <email>hpark@cop.ufl.edu.</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P46">CONFLICT OF INTEREST: The authors declare that there is no conflict of interest regarding the publication of this article.</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2022</year></pub-date><volume>64</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">432774</issue-id><fpage>96</fpage><lpage>104</lpage><pub-history><event event-type="nihms-submitted"><date><day>30</day><month>03</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>05</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>05</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 05:25:25.783"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1884413.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P1">To estimate the economic impact of providing universal hepatitis C virus (HCV) testing in commercially insured middle aged persons who inject drugs (PWIDs) in the United States.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">This study developed a dynamic ten-year economic model to project the clinical and economic outcomes associated with HCV testing among middle aged adult PWIDs, from a payer&#8217;s perspective. Costs related to HCV testing, direct-acting antiviral (DAA), and liver-related outcomes between the (1) current HCV testing rate (i.e., 8%) and (2) universal HCV testing rate (i.e., 100%) were compared. Among patients testing positive, 21% of those without cirrhosis and 48% with cirrhosis were assumed to initiate DAAs. Sensitivity analyses were performed to identify variables (e.g.: DAA drugs costs, HCV testing costs, DAA treatment rate) influencing this study&#8217;s conclusion. </p></sec><sec id="S3"><title>Results:</title><p id="P3">The model predicts that during the 10-year period, universal HCV testing will cost an additional $242 per PWID to the payers&#8217; health care budgets compared to the current scenario. Sensitivity analyses demonstrated values ranging from $1,656 additional costs to $1,085 cost savings across all varied parameters and scenarios. 80% of the current DAA costs indicated that cost savings will be $383 per PWID.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P4">Universal HCV testing among PWIDs would not achieve cost savings within 10 years, with the cost of DAAs contributing the most to the spending. To promote the universal HCV testing among PWIDs, decreasing DAA costs and sustainable funding streams for HCV testing should be considered. </p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>